Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. How medical device risk management is connected with design controls
Medical device design controls play an important role when it comes to risk management, but the relationship isn’t always immediately clear.
Intended use is especially important, says Jon Speer, founder of Greenlight.guru (Indianapolis), which markets a cloud-based quality management software. Read more
4. Bioventus wins FDA nod for Durolane OA joint lubrication product
Bioventus said today it won FDA approval for its Durolane injectable product designed for joint lubrication and treating pain associated with knee osteoarthritis.
Durolane is a single-injection, hyaluornic acid product designed to lubricate joints to treat pain associated with knee osteoarthritis, Durham, N.C.-based Bioventus said. The company acquired it last December from Galderma for an undisclosed amount. Read more
3. Medtronic launches long-term PLF, TLIF Infuse bone protein study
Medtronic said today it launched a long-term clinical study of its Infuse bone graft for use during posterolateral fusion and transforaminal lumbar interbody fusion spine procedures.
The 1st patient in the study was enrolled at Indiana’s Fort Wayne Orthopedics and underwent a procedure led by Dr. Kevin Rahn and Dr. Robert Shugart, Fridley, Minn.-based Medtronic said. Read more
2. Novartis CEO departs, leaving corner office to Harvard doc
Novartis‘ chief executive Joseph Jimenez is slated to leave his post next February, the drugmaker reported over the weekend. The CEO’s surprise departure leaves the corner office to Dr. Vasant Narasimhan, who currently serves as the company’s CMO and global head of drug development.
The move comes just days after Novartis won FDA approval for its breakthrough CAR-T leukemia therapy – the first of its kind to be cleared in the U.S. Read more
1. Teleflex to pay $1.1B for NeoTract
Teleflex said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment.
The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days. Read more